Supreme Court Patent Judgments India.
SUPREME COURT PATENT JUDGMENTS – INDIA
1. Novartis AG v. Union of India & Others (2013) – “Gleevec Case”
Citation: (2013) 6 SCC 1
Facts:
Novartis sought a patent in India for the beta-crystalline form of imatinib mesylate, marketed as Gleevec (used in cancer treatment).
The Indian Patent Office refused the patent under Section 3(d) of the Patents Act, 1970, arguing it was a mere “incremental improvement” or new form of a known substance without enhanced efficacy.
Issues:
Can a new form of a known drug be patented under Indian law?
Does Section 3(d) violate TRIPS obligations?
Held:
The Supreme Court upheld the rejection.
Section 3(d) prevents “evergreening” (extending patent life through minor modifications).
The new form must show enhanced therapeutic efficacy over the known substance to be patentable.
Significance:
Landmark in pharma patent law.
Protects affordable medicines in India.
Clarified strict standards for incremental inventions.
2. Bayer Corporation v. Union of India (2014) – Patent Revocation & Compulsory Licensing
Facts:
Bayer’s patent on Nexavar (sorafenib) for cancer treatment was challenged under Section 84 for compulsory licensing.
Natco Pharma applied for a compulsory license, citing unaffordability for Indian patients.
Issues:
Can the government grant compulsory licenses for patented drugs?
What constitutes “reasonable affordability” and “public need”?
Held (Supreme Court in later references on appeal & discussion):
Compulsory licensing is permitted under Sections 84 & 100 of the Patents Act.
Patents do not grant absolute rights to prevent public access.
Significance:
Affirms public health over commercial interests.
Encourages generic competition in essential medicines.
3. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2008-2009) – Compulsory Licensing & Injunctions
Facts:
Roche sought injunction against Cipla for selling generic Erlotinib, a patented cancer drug.
Cipla argued that Roche was charging excessive prices.
Issues:
Can a patent holder enforce exclusive rights when drug pricing restricts public access?
Held:
Supreme Court emphasized the balance between patent rights and public interest.
Injunctions may not be automatically granted in pharma patents if access to life-saving medicines is threatened.
Significance:
Reiterated public health considerations in patent enforcement.
Influenced pricing and licensing norms for essential drugs.
4. Bioshield v. Natco (2012) – Compulsory License Interpretation
Facts:
Natco applied for a compulsory license for Nexavar, citing Bayer’s patent.
The case involved interpretation of Sections 84–92 of the Patents Act.
Held:
Supreme Court clarified that non-working or non-affordable pricing of a patented invention can justify compulsory licensing.
Patents are not absolute monopolies; they exist to encourage innovation, not to deny public access.
Significance:
Strengthened access to essential medicines.
Encouraged generic competition for affordability.
5. Union of India v. V. Shanta (2001) – Patentability & Research Exemptions
Facts:
Focused on research exemptions under Section 107A.
Researchers and hospitals challenged restrictions on using patented compounds for research.
Held:
Patents cannot block bona fide research or experimentation.
Use for experimental purposes is allowed without infringement liability.
Significance:
Protects academic and clinical research.
Clarifies scope of experimental use exemption in India.
6. Monsanto v. Nuziveedu Seeds (2018) – Plant Patents & Biotech
Facts:
Monsanto’s patent on Bt cotton technology was challenged by Nuziveedu Seeds for non-infringement claims.
Held:
Indian courts recognize patents on genetically modified seeds under the Patents Act (as per Plant Varieties Protection Act exemptions).
Patents extend only to specific genetic modifications, not naturally occurring traits.
Significance:
Clarifies biotech patent boundaries.
Protects innovation while allowing farmers’ traditional practices under certain conditions.
7. Novartis v. Union of India – Subsequent Interpretation (2015)
Significance:
Reaffirmed Section 3(d) as a stringent filter against minor pharmaceutical modifications.
Supreme Court emphasized evidence-based demonstration of therapeutic improvement.
SUMMARY OF KEY PRINCIPLES FROM SUPREME COURT PATENT JUDGMENTS
Section 3(d) is a bar to evergreening (Novartis).
Compulsory licensing can override patent exclusivity for public health (Bayer/Natco).
Experimental use is exempt from infringement (Shanta case).
Balance of monopoly and public interest is central to patent enforcement (Roche, Bayer).
Genetically modified seeds and biotech inventions have patent scope, but not for naturally occurring traits (Monsanto).
RELATED Blog
comments